CSBR 10-Q Filings - Champions Oncology, Inc. SEC 10-Q
Champions Oncology (CSBR) reported Q2 2026 revenue of $15.2M, up 8.8% YoY, with a net loss of $426K. Cash reserves were $4.4M, and management expects funds to last until September 2027. Nine-month revenue rose to $45.6M, but net income turned to a loss of $0.5M. Operating cash flow was negative $2.5M, with $7.1M in cash remaining.
How this was made
The 30-second read
Why it matters
The disclosed numbers are the first public release of the quarter's results, providing fresh data for traders.
Market read
First‑time earnings disclosure for a micro‑cap biotech; modest revenue growth but continued losses keep the stock vulnerable.
What to watch
Potential upcoming partnership announcements or FDA data could materially shift outlook beyond the modest Q2 numbers.
Background
The article aggregates recent 10‑Q filings for Champions Oncology, summarizing quarterly financials and cash position.
Ticker impact
Champions Oncology reported higher revenue but continued modest losses for the quarter ended July 31, 2026, with net loss of $0.426M and cash of $4.4M.
Potential modest downside pressure as loss persists, but cash runway may support stability.
Revenue growth is modest and losses remain, limiting upside; however, management's cash guidance reduces immediate liquidity concerns.
Market effects
Biotech/oncology data‑licensing sector sees incremental revenue growth but ongoing expense pressure.
U.S. small‑cap biotech segment may see slight bearish tilt.
Limited; impact confined to niche oncology data services market.
Counterpoint
Despite losses, the extended cash runway and growing data‑license revenue could support a short‑term rally.
Key entities
- companyChampions Oncology, Inc.
U.S. listed biotech firm focused on oncology data licensing.